Research programme: tumour necrosis factor-alpha secretion inhibitors - BiokineAlternative Names: BKT-104; BTT-1507
Latest Information Update: 02 Mar 2017
$50 / €47 *
At a glance
- Originator Biokine Therapeutics
- Developer Biotie Therapies Corp.
- Mechanism of Action Tumour necrosis factor-alpha convertase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 12 Aug 2005 Discontinued - Preclinical for Psoriasis in Israel (PO)
- 12 Jan 2005 BKT 104 has been licensed to BioTie Therapies worldwide
- 12 Jan 2005 Preclinical trials in Psoriasis in Israel (PO)